Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock

  • Sorrento Therapeutics Inc SRNE has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock.
  • Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% royalty of the annual net sales.
  • The acquisition will include late clinical-stage drug Abivertinib, AC0058, AC0939, and ACEA's extensive proprietary library of small molecules (over 1,000,000 compounds).
  • Lead candidate abivertinib is a small molecule tyrosine kinase inhibitor that selectively targets both a mutant form of the epidermal growth factor receptor and Bruton's tyrosine kinase. It is currently being studied as a Phase 2 treatment for COVID-19-induced respiratory compromise in the U.S. and Brazil.
  • AC0058 a BTK inhibitor, is currently in a Phase 1b trial for Lupus patients in the U.S.
  • The acquisition will also include ACEA's facility located in Quzhou, China, on a 23-acre campus with five buildings.
  • The facility currently can manufacture up to 5,000 kg/year of APIs and 50 million capsules of the final drug product.
  • The merger is expected to close in the second quarter of 2021.
  • Price Action: SRNE shares gained 1.5% at $8.13 in market trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!